Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 1 May 2015

Galderma steps into the Nutraceutical Market

Galderma entered the functional food market thanks to its acquisition of certain assets of Innéov Group. The company, a global leader committed to dermatology and skin health, is fully-owned by Nestlé Skin Health. On April 24th Nestlé Skin Health announced that Galderma, its company focused on medical solutions, has come to an agreement under which it […]

May 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Biocartis shakes Euronext with an IPO that raised €100M

Last Monday, Belgian Biocartis launched an IPO that quickly raised €100M; the offering was closed a week ahead of schedule. The unquestionable interest of the investors, both in Belgium and internationally, shows the company’s potential and the appeal of its technology. The company, which raised €64.5M in September in a private financial round, intends to […]

April 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 29 Apr 2015

Cytena greets €1.1M of Seed Capital

Cytena and its cy-Clone device to separate single cells received €1.1M from a consortium made up of a private investor and the High-Tech Gründerfonds (HTGF). Cytena will use this capital injection primarily to launch its product and to expand its marketing and distribution activities. The cy-Clone, cytena’s newest innovation, is a laboratory device that enables the […]

April 29, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

European GMOs: which side are you on?

Last week, the European Commission approved 19 GMOs, the first authorizations since 2013. Shortly after, different reactions showed up, with some people more willing to celebrate than others. While GMOs are widely grown in America and Asia, Europe is still reluctant to this new technology. These authorizations came after a year of European blockage. But […]

April 29, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Giant Baupost Group bets on Biotie

Finland-based Biotie Therapies will receive an investment of more than €92M from Baupost group. However, the investment is conditional and linked to the result of the appointment of a new board member expected for the 26th of May. Seth Klarman’s billionaire Baupost group will back Biotie on its way to develop tozadenant, its lead product candidate. The […]

April 29, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 28 Apr 2015

PEP-Therapy Raised €1.3 Million in Seed Capital

France-based PEP-Therapy has raised €1.3M in initial funding. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable the cancer-focused company to undertake regulatory development of its first therapeutic product, a biomarker. The biomarker works as a predictive for foreseeing the effectiveness of a cancer treatment. The […]

April 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 28 Apr 2015

Will 2015 be the year of biosimilars?

The Biosimilar drug field is growing fast despite the tight regulatory, business and financial challenges it faces. The industry is forecasted to be worth up to €23Bn by 2020. To explore the market opportunities for biosimilars, it is necessary to be aware of all the latest news and to stand at the forefront of the current landscape […]

April 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Apr 2015

Are personalized treatments for lung cancer underutilized?

Results from a new global survey of lung cancer oncologists have shown that, despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for Epidermal Growth Factor Receptor mutations (EGFR), a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype. The survey, with […]

April 23, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Vaccines against Parasites, on the Horizon with XstalBio

XstalBio has commenced work on an €9.3M EU Funded Horizon 2020 project to develop vaccines that protect cattle, sheep and poultry, against infection by parasites. The 4 year “PARAGONE” collaboration involves 17 partners from Europe, Uruguay and China and will aim to move several candidate vaccines from the laboratory into practical field trials. XstalBio, as […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

OncoBEAM blood test arrives to Europe

Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex’s OncoBEAM services throughout Germany, Austria and Switzerland. IndivuTest will be responsible for commercial and sample logistics, with all testing being performed […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

Galderma steps into the Nutraceutical Market

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

A new Microfluidic Chip technology raised €1.9Million

Biocartis shakes Euronext with an IPO that raised €100M

Cytena greets €1.1M of Seed Capital

European GMOs: which side are you on?

Giant Baupost Group bets on Biotie

PEP-Therapy Raised €1.3 Million in Seed Capital

Will 2015 be the year of biosimilars?

Are personalized treatments for lung cancer underutilized?

Vaccines against Parasites, on the Horizon with XstalBio

OncoBEAM blood test arrives to Europe

Subscribe to our newsletter to get the latest biotech news!